The Cancer Stem Cell Therapies Market, 2017-2030' report examines the current landscape and the future outlook of the growing pipeline of products targeting CSCs. We identified over 150 molecules that are currently being investigated as therapeutic interventions for the elimination of CSCs. Over the past few years, this burgeoning field of research has captured the interest of several players in the pharmaceutical industry.
Cancer stem cells (CSCs) are known to be rare, immortal cells within a tumor that can both self-renew and differentiate into several cell types that form the tumor mass. Over time, the development of CSCs has been shown to be associated with several signaling pathways, which regulate the survival and proliferation of these cells. Presently, a number of initiatives are underway to explore specific targets that can be used to selectively eliminate cancer stem cells and, thereby, confer therapeutic benefits to patients suffering from various forms of cancers.
The presence of CSCs has been established in various cancers, including oesophageal cancer, gastric cancer, intestinal cancer, colon cancer, hepatic cancer and pancreatic cancer. However, it is postulated that these self-renewing CSCs represent only a small fraction of the cell population (approximately 1%) within the bulk tumor mass. The frequent failure in trying to treat advanced cancers using the current standard of care therapies has been attributed to the presence of CSCs as these cells actively resist all methods of treatment, including chemotherapy and radiotherapy.
The objective of the ongoing R&D is to develop novel CSC directed treatments that can combat complications, such as off target toxicities and disease relapse, associated with the current standard of care treatments. In fact, between January 2008 and December 2016, the number of publications in this domain grew at an annualized rate of 10.4%; overall, there are over 9000 publications available on PubMed, indicating the extensive research activity unfolding in this domain.
Amongst other elements, the report features:
An elaborate discussion on the origin, properties and methods for identification of CSCs. It covers the key therapeutic strategies that are being investigated for eliminating CSCs; these include targeting signaling pathways, targeting cancer stemness factors and related surface markers, inhibiting ATP-binding cassette transporters, targeting the tumor microenvironment, and the induction of apoptosis in CSCs.
A review of the overall landscape of the CSC therapy market with respect to the phase of development, key therapeutic targets, oncological indications, mode of administration, type of molecule (small molecule, monoclonal antibody, peptides, bispecific antibody, gene therapy, fusion proteins and other biologics), geographical distribution of R&D efforts and the key players in this domain.
A detailed publication analysis on more than 340 articles that have been published between September 2016 and October 2017, highlighting the key focus areas of the ongoing research activity in this field.
Comprehensive profiles of phase III and marketed drugs featuring a brief company overview and financial details, product description, mechanism of action, current status of development, active clinical trials, key clinical trial results, manufacturing information, dosage and sales information, collaborations established related to the product, and a comprehensive future outlook of the developer. Additionally, the report also includes profiles of drugs that are in phase II of clinical development.
Insightful representations of the distribution of CSC targeting molecules across various parameters, such as target molecular pathway, therapeutic area, type of molecule and highest phase of development. The report features a bull's eye analysis to specifically highlight the most popular targets from a clinical standpoint. In addition, we have provided a comprehensive overview (in the form of a 2 X 2 matrix) of the competitive landscape of developers, highlighting each developer's product portfolio, company size and location of headquarters.
An analysis depicting the prevalent and emerging trends related to CSC therapies as observed on the social media platform, Twitter. In addition to the yearly trend, the analysis highlights the most talked about therapeutic targets for CSC therapies and the popular cancer indications.
One of the key objectives of the report was to estimate the future size of the CSC therapy market, specifically in the US and EU. We adopted a bottom-up approach to evaluate the likely success and growth of marketed drugs and those that are in phase II and phase III of clinical development, over the next 10-15 years. The insights generated on the future opportunity are segmented on the basis of key indications, important target strategies and key products. In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the period 2017-2030, namely the conservative, base and optimistic scenarios, which represent three different tracks of the industry's evolution.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The report presents details of conversations with (in alphabetical order of company name) Stephen Franklin (CEO, Evgen Pharma), Steven Swanson (Senior Vice President, ImmunoCellular Therapeutics) and Jaffer Ajani (Researcher at MD Anderson Cancer Center).
Key Topics Covered:
1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION 3.1. An Overview of Cancer 3.2. Tracing the Origins of Cancer 3.2.1. Origin of Cancer Stem Cells 18.104.22.168. Stem Cell Mutations 22.214.171.124. Adult Stem Cells 126.96.36.199. De-differentiation 3.2.2. Properties of Cancer Stem Cells 188.8.131.52. Self-renewal, Proliferation and Differentiation 184.108.40.206. Dysregulation of Molecular Signaling Pathways 220.127.116.11. Presence of Specific Surface Markers 18.104.22.168. Expression of Efflux Transporter 3.2.3. Identification of Cancer Stem Cells 3.3. Therapeutic Strategies for Targeting Cancer Stem Cells 3.3.1. Targeting Cancer Stem Cell Signaling Pathways 22.214.171.124. Hedgehog Signaling Pathway 126.96.36.199. Notch Signaling Pathway 188.8.131.52. Wnt Signaling Pathway 184.108.40.206. BMI1 Signaling Pathway 220.127.116.11. Cross-Talk Between Signaling Pathways 3.3.2. Targeting Cancer Stemness Factors 3.3.3. Silencing Oncogenes 3.3.4. Targeting Cancer Stem Cell Surface Markers 3.3.5. Inhibiting ATP-Binding Cassette Transporters 3.3.6. Targeting the Tumor Microenvironment 3.3.7. Regulating Epigenetic Changes 3.3.8. Induction of Apoptosis in Cancer Stem Cells 3.3.9. Induction of Differentiation in Cancer Stem Cells 3.4. Future Perspectives
4. COMPETITIVE LANDSCAPE 4.1. Chapter Overview 4.2. Cancer Stem Cell Therapies: Development Pipeline 4.2.1. Distribution by Phase of Development 4.2.2. Distribution by Therapeutic Area 4.2.3. Distribution by Therapeutic Strategies 4.2.4. Distribution by Type of Molecule 4.2.5. Distribution by Route of Administration 4.2.6. Distribution by Geography of Developer 4.2.7. Most Active Industry Players
5. KEY INSIGHTS 5.1. Chapter Overview 5.2. Cancer Stem Cell Therapies: Clinical Development Analysis of Potential Target Pathways 5.3. Cancer Stem Cells Therapies: Clinical Development Analysis of Potential Molecular Targets 5.4. Cancer Stem Cell Therapies: Clinical Development Analysis based on Therapeutic Area, Type of Molecule and Phase of Development 5.5. Cancer Stem Cell Therapies: Product Competitiveness Analysis based on Developer Landscape
6. EMERGING TRENDS ON SOCIAL MEDIA 6.1. Chapter Overview 6.2 Cancer Stem Cells: Trends on Twitter 6.2.1. Year-wise Activity Analysis (2012-2017) 6.2.2. Popular Therapeutic Targets on Twitter 6.2.3. Popular Indications on Twitter
7. PUBLICATION ANALYSIS 7.1. Chapter Overview 7.2. Cancer Stem Cells: Publications Analysis 7.2.1. Analysis by Key Journals 7.2.2. Analysis by Most Popular Targets
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS 10.1. Chapter Overview 10.2. Scope and Limitations 10.3. Forecast Methodology 10.4. Overall Cancer Stem Cell Therapies Market, 2017-2030 10.4.1. Cancer Stem Cell Therapies Market: Distribution by Indication 10.4.2. Cancer Stem Cell Therapies Market: Distribution by Therapeutic Target 10.4.3. Cancer Stem Cell Therapies Market: Distribution by Type of Molecule 10.4.4. Cancer Stem Cell Therapies Market: Share of Products 10.5. Cancer Stem Cell Therapies Market: Individual Drug Forecasts 10.5.1. Erivedge 10.5.2. Odomzo 10.5.3. Napabucasin 10.5.4. BL-8040 10.5.5. Rova-T 10.5.6. Imetelstat 10.5.7. BHQ 880 10.5.8. CRLX101 10.5.9. Glasdegib / PF-04449913 10.5.10. Amcasertib / BBI503 10.5.11. CX-02 10.5.12. GLG-801 10.5.13. MDNA55 10.5.14. ONC201 10.5.15. Patidegib / IPI-926 / Saridegib 10.5.16. Reparixin 10.5.17. SUBA-Itraconazole 10.5.18. VicOryx 10.5.19. Sulforadex / SFX-01 10.5.20. Ibrutinib 10.5.21. PT2385 10.5.22. GO-203 10.5.23. AZD9150 / ISIS-STAT3-2.5Rx
11. CONCLUSION 11.1. Extensive Research is being Carried out to Harness the Therapeutic Potential Related to Targeting Cancer Stem Cells 11.2. Such Targeted Therapies have Garnered the Interest of both Industry and Non-Industry Players 11.3. With Two Marketed Products and Several Molecules in the Clinical / Preclinical Stages, the Pipeline Appears to be Promising 11.4. Majority of Drugs / Therapies are being Developed to Target Cancer Stem Cell Signaling Pathways 11.5. The Field has Witnessed the Establishment of Several Partnerships and Received Significant Support from Venture Capital Investors 11.6. With Promising Clinical Results, These Therapies are Poised to Achieve Accelerated Growth in the Foreseen Future
12. INTERVIEW TRANSCRIPTS 12.1. Chapter Overview 12.2. Stephen Franklin, CEO, Evgen Pharma 12.3. Steven Swanson, Senior Vice President, Research, ImmunoCellular Therapeutics 12.4. Jaffer Ajani, Researcher, MD Anderson Cancer Centre
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Advanced Accelerator Applications
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb (BMS)
Cancer Therapy and Research Center
Centre Lon Brard
D3 (Drug Discovery and Development)
Dana-Farber Cancer Institute
Duke University Medical Center
Foresite Capital Management
Fox Chase Cancer Center
Glaxo Smith Kline (GSK)
inVentiv Health Clinical
Maastricht University Medical Center
Manchester Cancer Research Centre
Massachusetts General Hospital
MD Anderson Cancer Center
National Cancer Institute (NCI)
National Institute of Neurological Disorders and Stroke (NINDS)